Century Therapeutics, Inc. IPSC
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Century Therapeutics, Inc. (IPSC) is a healthcare company listed in the US with a market value of about $300M. In fiscal year 2025 it had revenue of $109M and net income of -$10M, a net margin of -8.8%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -31%.
About Century Therapeutics
Century Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $5M in 2022 to $109M in 2025, growth of about 175.9% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 167% over three years (dilution for shareholders). It spends 88% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $109M | $7M | $2M | $5M | — | — |
| Net income | -$10M | -$127M | -$137M | -$131M | -$96M | -$54M |
| Free cash flow | -$105M | -$110M | -$102M | -$17M | -$134M | -$51M |
| EPS (diluted) | $-0.07 | $-0.81 | $-1.15 | $-1.48 | $-1.48 | $-3.58 |
| Net margin | -8.8% | -1920.9% | -6115.1% | -2518.4% | — | — |
| ROIC | -8.5% | -50.7% | -49.7% | -30.0% | -17.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $4.75, 188% above the current price; targets range from $2.00 to $8.00; the consensus rating is “Buy”; expected EPS is $-0.52 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Century Therapeutics pay a dividend?
Not currently.
Is Century Therapeutics a good stock to buy?
We do not give buy or sell advice. Century Therapeutics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.